|
AVAX Technologies wants to turn cancer cells into cancer fighters. The company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate M-Vax is intended as a post-surgical treatment for late-stage melanoma, but the company is also developing vaccine candidates to fight ovarian cancer (O-Vax) and non-small cell lung cancer (L-Vax). The company also offers contract manufacturing services to other biotech and pharmaceutical companies.
|
| | | Contact Information | |
Address: |
2000 Hamilton St., Ste. 204
Philadelphia, PA 19130
| | Phone: | 215-241-9760 | | Fax: | 215-241-9684 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2007): | 0.60 M | | Revenue Growth (1 yr): | (-16.00%) | | Employees (2007): | 29 | | Employee Growth (1 yr): | 20.80% |
|
|
Key People
| | • |
Chairman:
John K. A. Prendergast
| | • |
President, CEO, and Director:
François R. Martelet
| | • |
CFO and Director:
Richard P. (Rich) Rainey
|
|
|
